Company intelligence / Profile preview

Bright Minds Biosciences Inc.

New York, New York, United Statesbrightmindsbio.com ↗

Ownership: Public · DRUG
Development stage: Preclinical

Overview

BMB-101, the company's lead candidate, has completed Phase 1 clinical trials demonstrating safety and tolerability in healthy participants. A Phase 2 trial (BREAKTHROUGH Study) began in September 2024 to evaluate BMB-101 in adult patients with classic Absence Epilepsy and Developmental Epileptic Encephalopathy (DEE), with results expected within 18-20 weeks[7][9].

Therapeutic areas: PsychiatryNeurology
Modalities: Small moleculesserotonergic compounds
Industry: Biotech

Drug pipeline

5 assets

BMB-101

4 more assets in the full pipeline.

Request access →

Partnerships

National Institutes of Health (NIH)AECTNEpilepsy Study Consortium

Financials

Market cap: $636.2M
Total revenue: $0
Enterprise value: $327.9M

Beyond the preview

Go deeper on Bright Minds Biosciences Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bright Minds Biosciences Inc..

Explore the full profile